Aldeyra The
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $128.5M
- Price
- $2.13
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.79%
- Volume
- 3.1M
Quote data as of 6:09 AM ET
About
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Quick stats
Shares outstanding60.3M
Computed float49.5M
Float sourceUnknown
Cash runway (months)Unknown
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001341235
Websitehttps://www.aldeyra.com
AI Summary
AI-generated2d agominorbullishexecutive changeLevicept Appoints Darlene Deptula-Hicks as CFO
Levicept appointed Darlene Deptula-Hicks as its new Chief Financial Officer, replacing acting CFO Nicholas Stern.
Deptula-Hicks brings extensive biotech capital-raising and M&A experience, having previously served as CFO at F-star Therapeutics and held board roles at Aldeyra Therapeutics and Lytix Biopharma.
The appointment coincides with the company’s push to advance its lead asset LEVI-04, which completed a Phase II trial in over 500 patients showing pain relief and potential disease modification.